Cardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database.

ABSTRACT:

Introduction

Advances in the early detection and treatment of cancer have significantly improved the prognosis of patients with cancer. Tyrosine kinase inhibitors (TKIs) are effective targeted treatments for various malignancies that act by inhibiting kinase activity. Although these drugs share a common mechanism of action, they differ in their targeted kinases, pharmacokinetics, and side effects. TKIs can cause cardiovascular side effects, which adversely affect the prognosis of cancer survivors. This study aimed to assess the risk of cardiac toxicity associated with TKIs using the World Health Organization Global Database, VigiBase.

Methods

We conducted a cross-sectional analysis of data from VigiBase, a comprehensive global database of suspected drug reactions. The datase

SUBMITTER: Igawa Y 

PROVIDER: S-EPMC11646760 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature